期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 11, 期 4, 页码 446-475出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2013.0059
关键词
-
类别
资金
- Bristol-Myers Squibb Company
- Genentech, Inc.
- Agensys, Inc.
- sanofi-aventis U.S. LLC
- Endo Pharmaceuticals
- GlaxoSmithKline plc
- Bayer HealthCare
- CureTech Ltd.
- Eli Lilly and Company
- Merck Co., Inc.
- Novartis Pharmaceuticals Corporation
- Onyx Pharmaceuticals, Inc.
- Alton Pharmaceuticals
- Argos Therapeutics, Inc.
- Biovex, Inc.
Bladder cancer is the fourth most common cancer in the United States. Urothelial carcinoma that originates from the urinary bladder is the most common subtype. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide recommendations on the diagnosis and management of non muscle-invasive and muscle-invasive urothelial carcinoma of the bladder. This version of the guidelines provides extensive reorganization and updates on the principles of chemotherapy management. (JNCCN 2013;11:446-475)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据